Mei-Shi Announces Implementation Status of Subsidiary's Plan to Rectify Excessive Lending to Third Parties

1. Date of Event: June 26, 2026 2. Company Name: Alvogen Pharma US Inc. 3. Relationship with Company (please enter 'Company' or 'Subsidiary'): Subsidiary 4. Cross-shareholding Ratio: Subsidiary fully owned (100%) by the Company 5. Reason for Occurrence: In accordance with the Financial Supervisory Commission's Notice No. 1150335969, this announcement is made to disclose that the Company's subsidiary has completed its improvement plan for excessive fund lending by June 30, 2026. The board of directors is required to oversee and control the implementation of these improvements. 6. Response Measures: (1) The U.S. subsidiary established operational procedures for lending funds to others by the end of March 2026, in compliance with the 'Regulations Governing Lending, Endorsement, and Guarantee by Publicly Issued Companies'. (2) The Company revised its internal procedures for fund lending and endorsement guarantees, which was approved during the 2026 annual shareholders' meeting. (3) The Company reported the completion of improvement measures to the Audit and Risk Management Committee on June 25, 2026, and to the Board of Directors on June 26, 2026. 7. Other Matters to be Disclosed: If the entity involved in the event or resolution is a publicly issued company or above, this major information simultaneously qualifies as a matter having significant impact on shareholders' rights or securities prices under Article 7, Paragraph 9, Item 9 of the Enforcement Rules of the Securities and Exchange Act. However, no such matters apply in this case.